Loading...
XNASRNAZ
Market cap2mUSD
Dec 24, Last price  
3.46USD
1D
-3.42%
1Q
433.09%
IPO
-99.92%
Name

Transcode Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:RNAZ chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
94.64%
Rev. gr., 5y
%
Revenues
0k
Net income
-19m
L-47.21%
-453,440-764,143-2,738,330-6,938,469-35,129,936-18,546,095
CFO
-18m
L+14.67%
-299,572-508,508-492,971-5,266,885-15,762,512-18,074,535

Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
IPO date
Apr 28, 2021
Employees
19
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
19,419
18,764
6,194
Unusual Expense (Income)
NOPBT
(19,419)
(18,764)
(6,194)
NOPBT Margin
Operating Taxes
17,565
95
Tax Rate
NOPAT
(19,419)
(36,329)
(6,289)
Net income
(18,546)
-47.21%
(35,130)
406.31%
(6,938)
153.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
15,909
5,989
26,335
BB yield
-1,348.24%
-68.57%
-123.06%
Debt
Debt current
412
(2,016)
Long-term debt
489
Deferred revenue
Other long-term liabilities
4,347
Net debt
(1,866)
(4,968)
(22,842)
Cash flow
Cash from operating activities
(18,075)
(15,763)
(5,267)
CAPEX
(36)
(101)
(255)
Cash from investing activities
(36)
(101)
(252)
Cash from financing activities
15,909
6
25,517
FCF
(19,812)
(36,332)
(6,495)
Balance
Cash
2,768
4,968
20,826
Long term investments
Excess cash
2,768
4,968
20,826
Stockholders' equity
(46,416)
(27,869)
(10,304)
Invested Capital
48,508
31,110
28,692
ROIC
ROCE
EV
Common stock shares outstanding
179
16
11
Price
6.59
-98.78%
538.40
-73.50%
2,032.00
 
Market cap
1,180
-86.49%
8,734
-59.19%
21,401
 
EV
(686)
3,766
(1,441)
EBITDA
(18,902)
(18,666)
(6,151)
EV/EBITDA
0.04
0.23
Interest
51
17,565
95
Interest/NOPBT